[{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"f17e9f3e-aca2-40fd-9842-6769913d6623","acronym":"","url":"https://clinicaltrials.gov/study/NCT02520063","created_at":"2021-01-18T12:10:45.080Z","updated_at":"2025-02-25T15:42:33.018Z","phase":"Phase 1/2","brief_title":"Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer","source_id_and_acronym":"NCT02520063","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • letrozole • carotuximab IV (ENV-105)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/23/2019","start_date":" 02/23/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-27"},{"id":"6724b39f-08dd-46d5-950d-1b4b715f5e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT05061017","created_at":"2021-09-29T11:53:50.927Z","updated_at":"2024-07-02T16:34:58.857Z","phase":"Phase 2","brief_title":"Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)","source_id_and_acronym":"NCT05061017","lead_sponsor":"Diwakar Davar","biomarkers":" KRAS • BRAF • ALK • MET","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF • ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • pixatimod (PG545)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 02/05/2024","primary_completion_date":" 02/05/2024","study_txt":" Completion: 03/18/2024","study_completion_date":" 03/18/2024","last_update_posted":"2024-06-04"},{"id":"a2a285a5-555c-4e53-ba89-bdb5efd56b1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05401110","created_at":"2022-06-02T16:58:56.919Z","updated_at":"2024-07-02T16:35:12.049Z","phase":"Phase 1","brief_title":"Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05401110","lead_sponsor":"Karen Reckamp, MD, MS","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • carotuximab IV (ENV-105)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/15/2023","start_date":" 09/15/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-04-02"},{"id":"3cd29e52-af9d-4ffc-9f57-b8ce426e67cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05661201","created_at":"2022-12-22T15:59:18.931Z","updated_at":"2024-07-02T16:35:15.432Z","phase":"Phase 1","brief_title":"NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","source_id_and_acronym":"NCT05661201","lead_sponsor":"Georgetown University","biomarkers":" KRAS • ST2","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/12/2023","start_date":" 04/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-03-11"},{"id":"2724193d-44df-4903-9b86-2f4db953b4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06075849","created_at":"2023-11-19T04:16:12.935Z","updated_at":"2024-07-02T16:35:17.893Z","phase":"Phase 1","brief_title":"Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent","source_id_and_acronym":"NCT06075849","lead_sponsor":"Panolos Bioscience","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PB101"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-23"},{"id":"e8106815-807d-440d-af1d-1076b6e5a743","acronym":"","url":"https://clinicaltrials.gov/study/NCT05318443","created_at":"2022-04-08T21:52:56.841Z","updated_at":"2024-07-02T16:35:25.142Z","phase":"Phase 3","brief_title":"A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05318443","lead_sponsor":"Shanghai Institute Of Biological Products","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • SIBP-04 (bevacizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 512","initiation":"Initiation: 04/17/2020","start_date":" 04/17/2020","primary_txt":" Primary completion: 12/26/2022","primary_completion_date":" 12/26/2022","study_txt":" Completion: 01/12/2023","study_completion_date":" 01/12/2023","last_update_posted":"2023-12-27"},{"id":"10adfe7c-1a6c-43eb-9d18-a1d7306c999a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04166383","created_at":"2021-01-18T20:19:48.675Z","updated_at":"2024-07-02T16:35:29.876Z","phase":"Phase 2","brief_title":"VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT04166383","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ofranergene obadenovec (VB-111)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 08/09/2020","start_date":" 08/09/2020","primary_txt":" Primary completion: 04/12/2022","primary_completion_date":" 04/12/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-11-08"},{"id":"d6659ed0-a160-442d-9ebc-6110d6f497a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03161652","created_at":"2022-07-22T08:56:46.266Z","updated_at":"2024-07-02T16:35:39.044Z","phase":"Phase 2","brief_title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","source_id_and_acronym":"NCT03161652","lead_sponsor":"Carmen Clapp","biomarkers":" PRL","pipe":"","alterations":" ","tags":["PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lucentis (ranibizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/24/2017","start_date":" 05/24/2017","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-25"},{"id":"7d8b0eef-b03c-4911-b4a7-b91df81c3ecd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04365179","created_at":"2022-01-21T23:05:16.500Z","updated_at":"2024-07-02T16:36:06.876Z","phase":"Phase 1b","brief_title":"Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML","source_id_and_acronym":"NCT04365179","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerofe (84AA-API 14AA)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2022-07-22"},{"id":"58a31459-21df-4bd9-8abf-d104cc8e0d3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03634150","created_at":"2022-01-21T23:04:46.298Z","updated_at":"2024-07-02T16:36:22.458Z","phase":"Phase 1b","brief_title":"Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer","source_id_and_acronym":"NCT03634150","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/06/2018","start_date":" 09/06/2018","primary_txt":" Primary completion: 04/21/2020","primary_completion_date":" 04/21/2020","study_txt":" Completion: 04/21/2020","study_completion_date":" 04/21/2020","last_update_posted":"2021-10-26"},{"id":"0ab959d2-019e-4284-83c4-b2da168d5e81","acronym":"","url":"https://clinicaltrials.gov/study/NCT03059615","created_at":"2022-01-21T23:03:21.504Z","updated_at":"2024-07-02T16:36:42.508Z","phase":"Phase 2a","brief_title":"A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS","source_id_and_acronym":"NCT03059615","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/25/2018","start_date":" 10/25/2018","primary_txt":" Primary completion: 07/26/2020","primary_completion_date":" 07/26/2020","study_txt":" Completion: 07/26/2020","study_completion_date":" 07/26/2020","last_update_posted":"2020-07-31"},{"id":"06fa6d0c-d77a-44bd-bfad-6e5ced982114","acronym":"","url":"https://clinicaltrials.gov/study/NCT03181308","created_at":"2021-01-18T15:41:17.626Z","updated_at":"2024-07-02T16:36:43.875Z","phase":"Phase 1b","brief_title":"Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC","source_id_and_acronym":"NCT03181308","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" EGFR • PD-L1 • ROS1 • ALK1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ROS1 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 11/09/2017","start_date":" 11/09/2017","primary_txt":" Primary completion: 07/22/2019","primary_completion_date":" 07/22/2019","study_txt":" Completion: 07/22/2019","study_completion_date":" 07/22/2019","last_update_posted":"2020-06-24"},{"id":"c9a4cec3-a91c-4bce-b61e-71cb0817eced","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975519","created_at":"2021-01-18T08:59:39.076Z","updated_at":"2024-07-02T16:36:44.893Z","phase":"Phase 2a","brief_title":"A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT01975519","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 12/10/2013","start_date":" 12/10/2013","primary_txt":" Primary completion: 03/11/2019","primary_completion_date":" 03/11/2019","study_txt":" Completion: 03/11/2019","study_completion_date":" 03/11/2019","last_update_posted":"2020-05-20"},{"id":"01bd9776-4109-4734-9d40-8f7b153b539f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03780010","created_at":"2021-01-18T18:41:47.734Z","updated_at":"2024-07-02T16:36:54.192Z","phase":"Phase 1b","brief_title":"Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC","source_id_and_acronym":"NCT03780010","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" ALK1","pipe":"","alterations":" ","tags":["ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2019-10-28"},{"id":"f126f464-cd22-47b6-a106-83891f6a2732","acronym":"","url":"https://clinicaltrials.gov/study/NCT01326481","created_at":"2021-01-18T05:24:16.843Z","updated_at":"2024-07-02T16:37:01.637Z","phase":"Phase 1b","brief_title":"Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer","source_id_and_acronym":"NCT01326481","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 09/01/2014","primary_completion_date":" 09/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2019-03-18"},{"id":"48716b21-6535-4713-9a0f-a09659ac678b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306058","created_at":"2021-01-18T05:18:51.239Z","updated_at":"2024-07-02T16:37:03.540Z","phase":"Phase 1/2","brief_title":"Sorafenib and TRC105 in Hepatocellular Cancer","source_id_and_acronym":"NCT01306058","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ENG","pipe":"","alterations":" ","tags":["ENG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 02/11/2011","start_date":" 02/11/2011","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/09/2017","study_completion_date":" 06/09/2017","last_update_posted":"2019-01-23"},{"id":"7a4e6051-5b4f-43d4-bc82-22829467963b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01332721","created_at":"2021-01-18T05:25:58.887Z","updated_at":"2024-07-02T16:37:04.875Z","phase":"Phase 1b","brief_title":"Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated","source_id_and_acronym":"NCT01332721","lead_sponsor":"Tracon Pharmaceuticals Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2018-12-05"},{"id":"e83e2110-b8f6-4e45-9f60-dacc41f4a6ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT01727089","created_at":"2021-01-18T07:32:39.498Z","updated_at":"2024-07-02T16:37:07.431Z","phase":"Phase 2","brief_title":"Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01727089","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carotuximab IV (ENV-105)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 08/08/2017","primary_completion_date":" 08/08/2017","study_txt":" Completion: 08/08/2017","study_completion_date":" 08/08/2017","last_update_posted":"2018-08-28"},{"id":"35c486d5-bfcb-4625-9d4c-ee6c0baceebb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01690741","created_at":"2022-01-21T22:57:20.249Z","updated_at":"2024-07-02T16:37:09.631Z","phase":"Phase 1","brief_title":"Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies","source_id_and_acronym":"NCT01690741","lead_sponsor":"Immune System Key Ltd","biomarkers":" ST2","pipe":"","alterations":" ","tags":["ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerofe (84AA-API 14AA)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 12/19/2017","primary_completion_date":" 12/19/2017","study_txt":" Completion: 12/19/2017","study_completion_date":" 12/19/2017","last_update_posted":"2018-06-25"},{"id":"fa153fa1-88be-494d-a000-63ab41769eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00454194","created_at":"2021-01-18T01:36:36.230Z","updated_at":"2024-07-02T16:37:24.233Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00454194","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-03-21"}]